<p>Pfizer plans to submit data to the US Food and Drug Administration (FDA) on a fourth Covid shot soon, CEO Albert Bourla has said.</p>.<p>The US drugmaker is also working on a vaccine that protects against all coronavirus variants, Bourla told CNBC.</p>.<p>"I think we're going to submit to FDA significant progress of data about the need for a fourth dose, and they need to make their own conclusions, of course, and then CDC also. It's clear that there is a need in an environment of Omicron to boost the immune response," Bourla was quoted as saying in an interview.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/science-and-environment/should-public-health-measures-like-masking-continue-beyond-the-pandemic-data-shows-their-benefits-1090857.html" target="_blank">Should public health measures like masking continue beyond the pandemic? Data shows their benefits</a></strong></p>.<p>"We are making a vaccine that covers Omicron and all the other variants. There are so many trials that are going on right now, and a lot of them we'll start reading by the end of the month," he added.</p>.<p>Although Covid cases are on the decline and there is some semblance of normal returning, Bourla said: "I think the biggest question of all of us is how to stay ahead of the virus."</p>.<p>He said Pfizer is working on developing a vaccine that prevents infection in addition to preventing hospitalizations and severe cases of the virus, adding that making long-lasting vaccines is also a priority.</p>.<p>"We can't have vaccines every five, six months," Bourla said, adding: "We need to be able to move as soon as possible.</p>.<p><strong>Check out DH's latest videos:</strong></p>
<p>Pfizer plans to submit data to the US Food and Drug Administration (FDA) on a fourth Covid shot soon, CEO Albert Bourla has said.</p>.<p>The US drugmaker is also working on a vaccine that protects against all coronavirus variants, Bourla told CNBC.</p>.<p>"I think we're going to submit to FDA significant progress of data about the need for a fourth dose, and they need to make their own conclusions, of course, and then CDC also. It's clear that there is a need in an environment of Omicron to boost the immune response," Bourla was quoted as saying in an interview.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/science-and-environment/should-public-health-measures-like-masking-continue-beyond-the-pandemic-data-shows-their-benefits-1090857.html" target="_blank">Should public health measures like masking continue beyond the pandemic? Data shows their benefits</a></strong></p>.<p>"We are making a vaccine that covers Omicron and all the other variants. There are so many trials that are going on right now, and a lot of them we'll start reading by the end of the month," he added.</p>.<p>Although Covid cases are on the decline and there is some semblance of normal returning, Bourla said: "I think the biggest question of all of us is how to stay ahead of the virus."</p>.<p>He said Pfizer is working on developing a vaccine that prevents infection in addition to preventing hospitalizations and severe cases of the virus, adding that making long-lasting vaccines is also a priority.</p>.<p>"We can't have vaccines every five, six months," Bourla said, adding: "We need to be able to move as soon as possible.</p>.<p><strong>Check out DH's latest videos:</strong></p>